Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The "Obstructive Sleep Apnea - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides top line data relating to the clinical trials on ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 64.20% +3.11, ...